Von Willebrand Disease Epidemiology, Burden of Illness and Management: A Systematic Review

References

• Gralnick HR, Williams S, McKeown L, et al. A monomeric von Willebrand factor fragment, Leu-504--Lys-728, inhibits von Willebrand factor interaction with glycoprotein Ib-IX [corrected]. Proc Natl Acad Sci U S A. 1992;89(17):7880–7884. doi:10.1073/pnas.89.17.7880
   PubMed Web of Science ®Google Scholar
• Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103–2114. doi:10.1111/j.1538-7836.2006.02146.x
   PubMed Web of Science ®Google Scholar
• Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand’s disease. J Clin Invest. 1977;60(2):390–404. doi:10.1172/JCI108788
   PubMed Web of Science ®Google Scholar
• Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021;5(1):301–325. doi:10.1182/bloodadvances.2020003264
   PubMed Web of Science ®Google Scholar
• Leebeek FWG, Eikenboom JCJ. Von Willebrand’s disease. N Engl J Med. 2016;375(21):2067–2080. doi:10.1056/NEJMra1601561
   PubMed Web of Science ®Google Scholar
• Bowman M, Hopman WM, Rapson D, Lillicrap D, James P. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost. 2010;8(1):213–216. doi:10.1111/j.1538-7836.2009.03661.x
   PubMed Web of Science ®Google Scholar
• Cochrane group. Cochrane handbook for systematic reviews of interventions. Available from: http://training.cochrane.org/handbook. Accessed March 21, 2018.
   Google Scholar
• Institute of Medicine (IOM). Standards for systematic reviews. Available from: https://iom.nationalacademies.org/Reports/2011/Finding-What-Works-in-Health-Care-Standards-for-Systematic-Reviews/Standards.aspx. Accessed March 21, 2018.
   Google Scholar
• Orphanet. Von Willebrand disease. Available from: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=903. Accessed May 31, 2022.
   Google Scholar
• World Federation of Hemophilia. Report on the annual global survey; 2019. Available from: http://www1.wfh.org/publications/files/pdf-1806.pdf. Accessed May 31, 2022.
   Google Scholar
• Mannucci PM, Bloom AL, Larrieu MJ, Nilsson IM, West RR. Atherosclerosis and von Willebrand factor. I. Prevalence of severe von Willebrand’s disease in Western Europe and Israel. Br J Haematol. 1984;57(1):163–169. doi:10.1111/j.1365-2141.1984.tb02876.x
   PubMed Web of Science ®Google Scholar
• Abbonizio F, Hassan HJ, Riccioni R, Santagostino E, Arcieri R, Giampaolo A. New data from the Italian National Register of congenital coagulopathies, 2016 annual survey. Blood Transfus. 2020;18(1):58–66. doi:10.2450/2019.0211-18
   PubMed Web of Science ®Google Scholar
• FranceCoag. National statistics: von Willebrand disease. Available from: https://www.francecoag.org/SiteWebPublic/public/stats/stats_page.jsp?stat1=on&stat4=on. Accessed March 31, 2021.
   Google Scholar
• Giampaolo A, Abbonizio F, Arcieri R. Italian national registry of congenital coagulopathies. Blood Transfus. 2020;18(3):s30.
   PubMedGoogle Scholar
• United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO). UKHCDO annual report 2020 & bleeding disorder statistics for the financial year 2019/2020; 2020.
   Google Scholar
• Giampaolo A, Abbonizio F, Arcieri R, Hassan HJ. Italian registry of congenital bleeding disorders. J Clin Med. 2017;6(3):34. doi:10.3390/jcm6030034
   PubMed Web of Science ®Google Scholar
• Korea Hemophilia Foundation (KHF). Current Status. Available from: http://www.kohem.org/eng/load.asp?subPage=310. Accessed December 31, 2020.
   Google Scholar
• National Blood Authority of Australia. Australian bleeding disorders registry: annual report 2018-19; 2019. Available from: https://www.blood.gov.au/system/files/ABDR-Annual-Report-2018-19-FINAL.pdf. Accessed November 23, 2021.
   Google Scholar
• Tatsunami S, Kuwabara R, Akita M, Mimaya J, Shirahata A, Taki M. Number of patients with coagulation disorders in Japan’s 2010 annual report from the research committee for the national surveillance on coagulation disorders in Japan. Haemophilia. 2012;18(3):84.
   Google Scholar
• Yoon HS, Han Y, Kim YJ, et al. Epidemiology of congenital bleeding disorders: a nationwide population-based Korean study. J Korean Med Sci. 2020;35(39):e350. doi:10.3346/jkms.2020.35.e350
   PubMed Web of Science ®Google Scholar
• Qu Y, Nie X, Yang Z, et al. The prevalence of hemophilia in mainland China: a systematic review and meta-analysis. Southeast Asian J Trop Med Public Health. 2014;45(2):455–466.
   PubMed Web of Science ®Google Scholar
• Alkaabi S, Alzadjali A, Wasifuddin M, et al. Spectrum, clinical characteristics and outcome of von Willebrand disease in Oman. Haemophilia. 2020;26(Suppl 2):142.
   PubMedGoogle Scholar
• Mansouritorghabeh H, Manavifar L, Banihashem A, et al. An investigation of the spectrum of common and rare inherited coagulation disorders in north-eastern Iran. Blood Transfus. 2013;11(2):233–240. doi:10.2450/2012.0023-12
   PubMed Web of Science ®Google Scholar
• Blatný J, Ovesná P The status of care for persons with von Willebrand disease registered within CNHP registry annual report; 2019. Available from: https://www.cnhp.cz/res/file/vysledky/cnhp_2019_vwd_print.pdf. Accessed August 19, 2022.
   Google Scholar
• Centers for Disease Control and Prevention. HTC population profile patient characteristics. Available from: https://www.cdc.gov/ncbddd/hemophilia/communitycounts/data-reports/2020-9/table-1-patient-characteristics-by-calendar.html. Accessed August 19, 2022.
   Google Scholar
• The World Bank. Population, Total – Australia; 2019. Available from: https://data.worldbank.org/indicator/SP.POP.TOTL?locations=AU. Accessed November 23, 2021.
   Google Scholar
• Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood. 1987;69(2):454–459.
   PubMed Web of Science ®Google Scholar
• Sap F, Kavakli T, Kavakli K, Dizdarer C. The prevalence of von Willebrand disease and significance of in vitro bleeding time (PFA-100) in von Willebrand disease screening in the Izmir region. Turk J Haematol. 2013;30(1):40–47. doi:10.4274/tjh.2011.0020
   PubMed Web of Science ®Google Scholar
• Abu-Douleh E, Al-Numair N, Albanyan A, Alsuliman A, Bayoumi N, Owaidah T. Prevalence of von Willebrand disease among university students in Riyadh, Saudi Arabia. J Appl Hematol. 2018;9(4):136–139. doi:10.4103/joah.joah_63_18
   Google Scholar
• Bowman M, Hopman WM, Rapson D, Lillicrap D, Silva M, James P. A prospective evaluation of the prevalence of symptomatic von Willebrand disease (VWD) in a pediatric primary care population. Pediatr Blood Cancer. 2010;55(1):171–173. doi:10.1002/pbc.22429
   PubMed Web of Science ®Google Scholar
• Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123(6):893–898. doi:10.1016/s0022-3476(05)80384-1
   PubMed Web of Science ®Google Scholar
• Shonde-Adebola KB, Shokunbi WA, Adebola MB. Prevalence of von Willebrand disease among Nigerian youths in Ibadan South-Western Nigeria. OALib. 2021;8:e7789. doi:10.4236/oalib.1107789
   Google Scholar
• Orphanet. Von Willebrand disease type 3. Available from: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=166096. Accessed April 19, 2021.
   Google Scholar
• Federici AB, Bucciarelli P, Castaman G, et al. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. Semin Thromb Hemost. 2011;37(5):511–521. doi:10.1055/s-0031-1281037
   PubMed Web of Science ®Google Scholar
• Federici AB, Bucciarelli P, Castaman G, et al. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood. 2014;123(26):4037–4044. doi:10.1182/blood-2014-02-557264
   PubMed Web of Science ®Google Scholar
• Holm E, Osooli M, Steen Carlsson K, Berntorp E. Cardiovascular disease-related hospitalization and mortality among persons with von Willebrand disease: a nationwide register study in Sweden. Haemophilia. 2019;25(1):109–115. doi:10.1111/hae.13642
   PubMed Web of Science ®Google Scholar
• Sanders YV, Giezenaar MA, Laros-van Gorkom BA, et al. von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost. 2014;12(7):1066–1075. doi:10.1111/jth.12586
   PubMed Web of Science ®Google Scholar
• Siboni SM, Biguzzi E, Caiani V, Mistretta C, Bucciarelli P, Peyvandi F. Baseline factor VIII plasma levels and age at first bleeding in patients with severe forms of von Willebrand disease. Haemophilia. 2016;22(4):564–569. doi:10.1111/hae.12900
   PubMed Web of Science ®Google Scholar
• van Galen KPM, Sanders YV, Vojinovic U, et al. Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study. Haemophilia. 2015;21(3):e185–e192. doi:10.1111/hae.12670
   PubMed Web of Science ®Google Scholar
• Abe K, Dupervil B, O’Brien SH, et al. Higher rates of bleeding and use of treatment products among young boys compared to girls with von Willebrand disease. Am J Hematol. 2020;95(1):10–17. doi:10.1002/ajh.25656
   PubMed Web of Science ®Google Scholar
• Apostolova MH, Seaman CD, Comer DM, Yabes JG, Ragni MV. Prevalence and risk factors associated with hypertension in von Willebrand disease. Clin Appl Thromb Hemost. 2018;24(1):93–99. doi:10.1177/1076029616670258
   PubMed Web of Science ®Google Scholar
• Kumar S, Kishore R, Gupta V, Jain M, Shukla J. Prevalence and spectrum of von Willebrand disease in Eastern Uttar Pradesh. Indian J Pathol Microbiol. 2010;53(3):486–489. doi:10.4103/0377-4929.68287
   PubMed Web of Science ®Google Scholar
• Mokhtar GM, Tantawy AA, Adly AA, Telbany MA, El Arab SE, Ismail M. A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience. Blood Coagul Fibrinolysis. 2012;23(5):411–418. doi:10.1097/MBC.0b013e3283540bf8
   PubMed Web of Science ®Google Scholar
• Öner N, Gürsel T, Kaya Z, et al. Inherited coagulation disorders in Turkish children: a retrospective, single-center cohort study. Transfus Apher Sci. 2020;59(3):102728. doi:10.1016/j.transci.2020.102728
   PubMed Web of Science ®Google Scholar
• Sahoo T, Naseem S, Ahluwalia J, Marwaha RK, Trehan A, Bansal D. Inherited bleeding disorders in North Indian children: 14 years’ experience from a tertiary care center. Indian J Hematol Blood Transfus. 2020;36(2):330–336. doi:10.1007/s12288-019-01233-3
   PubMed Web of Science ®Google Scholar
• Seaman CD, Yabes J, Comer DM, Ragni MV. Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register. J Thromb Haemost. 2015;13(11):1999–2003. doi:10.1111/jth.13142
   PubMed Web of Science ®Google Scholar
• Trasi S, Shetty S, Ghosh K, Mohanty D. Prevalence and spectrum of von Willebrand disease from western India. Indian J Med Res. 2005;121(5):653–658.
   PubMed Web of Science ®Google Scholar
• Qureshi W, Hassan S, Dabak V, Kuriakose P. Thrombosis in VonWillebrand disease. Thromb Res. 2012;130(5):e255–e258. doi:10.1016/j.thromres.2012.09.005
   PubMed Web of Science ®Google Scholar
• Henriksson KM, Astermark J, Nilsson J-A, Baghaei F, Holmstrom M, Berntorp E. Survival among 5118 patients with bleeding disorders compared to matched controls in Sweden: results from a cohort register study. J Thromb Haemost. 2011;9(Suppl 2):222.
   Google Scholar
• Malec LM, Moore CG, Yabes J, Li J, Ragni MV. Postpartum haemorrhage in women with von Willebrand disease: an observational study of the Pennsylvania Health Care Cost Containment Council (PHC4) database. Haemophilia. 2015;21(5):e442–e445. doi:10.1111/hae.12739
   PubMed Web of Science ®Google Scholar
• Mittal V, Ahuja S, Acharya C, Palabindala V, Milner C. Obstetric and bleeding complications in pregnancy with von Willebrand disease: results from nationwide inpatient sample database 2003–2011. Blood. 2017;130(1):3373.
   Google Scholar
• Sidonio RF, Haley KM, Fallaize D. Impact of diagnosis of von Willebrand disease on patient outcomes: analysis of medical insurance claims data. Haemophilia. 2017;23(5):743–749. doi:10.1111/hae.13292
   PubMed Web of Science ®Google Scholar
• Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4(4):766–773. doi:10.1111/j.1538-7836.2006.01847.x
   PubMed Web of Science ®Google Scholar
• Chen YC, Yang L, Cheng SN, Hu SH, Chao TY. von Willebrand disease: a clinical and laboratory study of sixty-five patients. Ann Hematol. 2011;90(10):1183–1190. doi:10.1007/s00277-011-1266-4
   PubMed Web of Science ®Google Scholar
• de Wee EM, Sanders YV, Mauser-Bunschoten EP, et al. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost. 2012;108(4):683–692. doi:10.1160/TH12-04-0244
   PubMed Web of Science ®Google Scholar
• Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol. 2000;111(4):1236–1239. doi:10.1046/j.1365-2141.2000.02507.x
   PubMed Web of Science ®Google Scholar
• Sanders YV, Fijnvandraat K, Boender J, et al. Bleeding spectrum in children with moderate or severe von Willebrand disease: relevance of pediatric-specific bleeding. Am J Hematol. 2015;90(12):1142–1148. doi:10.1002/ajh.24195
   PubMed Web of Science ®Google Scholar
• Tosetto A, Badiee Z, Baghaipour MR, et al. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: results from 3WINTERS-IPS, an international and collaborative cross-sectional study. J Thromb Haemost. 2020;18(9):2145–2154. doi:10.1111/jth.14886
   PubMed Web of Science ®Google Scholar
• Hassan S, Qureshi W, Donthireddy V, Kuriakose P. Congenital von Willebrand’s disease and clinical hypothyroidism. Haemophilia. 2013;19(2):242–245. doi:10.1111/hae.12065
   PubMed Web of Science ®Google Scholar
• O’Brien SH, Stanek JR, Kaur D, McCracken K, Vesely SK. Laboratory monitoring during pregnancy and post-partum hemorrhage in women with von Willebrand disease. J Thromb Haemost. 2020;18(3):604–608. doi:10.1111/jth.14696
   PubMed Web of Science ®Google Scholar
• Xu Z, Dargaud Y, Chamouard V, et al. A single-centre study of management of pregnant women with von Willebrand disease. Haemophilia. 2019;25(1):e54–e57. doi:10.1111/hae.13653
   PubMed Web of Science ®Google Scholar
• Majluf-Cruz A, Velez-Ruelas MA, Gonzalez-Avila AI, et al. von Willebrand’s disease in Mexico: a pilot study. Haemophilia. 2013;19(2):231–235. doi:10.1111/hae.12016
   PubMed Web of Science ®Google Scholar
• Wilson E, Hanna F, Hyppa A, et al. Assessment of von Willebrand disease and pregnancy outcomes at regional Australian hospitals. Eur J Haematol. 2021;106(4):456–466. doi:10.1111/ejh.13562
   PubMed Web of Science ®Google Scholar
• Skeith L, Rydz N, O’Beirne M, Goodyear D, Li H, Poon MC. Pregnancy loss in women with von Willebrand disease: a single-center pilot study. Blood Coagul Fibrinolysis. 2017;28(5):393–397. doi:10.1097/MBC.0000000000000620
   PubMed Web of Science ®Google Scholar
• Sladic M, Smrkolj S. The impact of von Willebrand’s disease on pregnancy, delivery and postpartum period: a population-based study. Eur J Obstet Gynecol Reprod Biol. 2019;234:E155.
   PubMedGoogle Scholar
• Yousuf S, Cohen AJ, Eris E, Astsaturov A. A single institutional study on pregnancy outcomes in patients with von Willebrand disease. Blood. 2017;130(Suppl 1):1086. doi:10.1182/blood.V130.Suppl_1.1086.1086
   Google Scholar
• Rae C, Furlong W, Horsman J, et al. Bleeding disorders, menorrhagia and iron deficiency: impacts on health-related quality of life. Haemophilia. 2013;19(3):385–391. doi:10.1111/hae.12014
   PubMed Web of Science ®Google Scholar
• Kaur D, Vesely SK, Koch T, O’Brien SH. Quality and consequences of laboratory monitoring for von Willebrand disease during pregnancy. Am J Hematol. 2018;93(9):E31–E32.
   PubMed Web of Science ®Google Scholar
• Lu M, Oladapo A, Wu Y, Farahbakhshian S, Ewenstein B. Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States. J Manag Care Spec Pharm. 2021;27(2):175–185. doi:10.18553/jmcp.2020.20327
   PubMed Web of Science ®Google Scholar
• Tsagianni A, Comer DM, Yabes JG, Ragni MV. Von Willebrand disease and gastrointestinal bleeding: a national inpatient sample study. Thromb Res. 2019;178:119–123. doi:10.1016/j.thromres.2019.04.017
   PubMed Web of Science ®Google Scholar
• Haley KM, Sidonio RF, Abraham S, Cheng D, Recht M, Kulkarni R. A cross-sectional study of women and girls with congenital bleeding disorders: the American Thrombosis and Hemostasis Network cohort. J Womens Health. 2020;29(5):670–676. doi:10.1089/jwh.2019.7930
   PubMed Web of Science ®Google Scholar
• van Deukeren D, Mauser-Bunschoten EP, Schutgens REG, et al. The prevalence and burden of hand and wrist bleeds in von Willebrand disease. Haemophilia. 2019;25(1):e35–e38. doi:10.1111/hae.13632
   PubMed Web of Science ®Google Scholar
• van Galen KPM, Meijer K, Vogely HC, et al. Joint surgery in von Willebrand disease: a multicentre cross-sectional study. Haemophilia. 2016;22(2):256–262. doi:10.1111/hae.12834
   PubMed Web of Science ®Google Scholar
• Biss TT, Blanchette VS, Clark DS, et al. Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire. J Thromb Haemost. 2010;8(5):950–956. doi:10.1111/j.1538-7836.2010.03796.x
   PubMed Web of Science ®Google Scholar
• Atiq F, Meijer K, Eikenboom J, et al. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease. Br J Haematol. 2018;182(1):93–105. doi:10.1111/bjh.15277
   PubMed Web of Science ®Google Scholar
• Franchini M, Di Perna C, Santoro C, et al. Cancers in patients with von Willebrand disease: a survey from the Italian Association of Haemophilia Centres. Semin Thromb Hemost. 2016;42(1):36–41. doi:10.1055/s-0035-1564844
   PubMed Web of Science ®Google Scholar
• de Wee EM, Fijnvandraat K, de Goede-Bolder A, et al. Impact of von Willebrand disease on health-related quality of life in a pediatric population. J Thromb Haemost. 2011;9(3):502–509. doi:10.1111/j.1538-7836.2010.04175.x
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, Munn JE, Anderson TL, Lambing A, Tortella B, Witkop ML. Predictors of quality of life among adolescents and young adults with a bleeding disorder. Health Qual Life Outcomes. 2017;15(1):67. doi:10.1186/s12955-017-0643-7
   PubMedGoogle Scholar
• van Galen KPM, de Kleijn P, Foppen W, et al. Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study. Haematologica. 2017;102(9):1486–1493. doi:10.3324/haematol.2017.168617
   PubMed Web of Science ®Google Scholar
• Xu Y, Deforest M, Grabell J, Hopman W, James P. Relative contributions of bleeding scores and iron status on health-related quality of life in von Willebrand disease: a cross-sectional study. Haemophilia. 2017;23(1):115–121. doi:10.1111/hae.13062
   PubMed Web of Science ®Google Scholar
• van Galen KPM, Timmer M, de Kleijn P, et al. Long-term outcome after joint bleeds in von Willebrand disease compared to haemophilia A: a post hoc analysis. Thromb Haemost. 2018;118(10):1690–1700. doi:10.1055/s-0038-1670704
   PubMed Web of Science ®Google Scholar
• Govorov I, Ekelund L, Chaireti R, et al. Heavy menstrual bleeding and health-associated quality of life in women with von Willebrand’s disease. Exp Ther Med. 2016;11(5):1923–1929. doi:10.3892/etm.2016.3144
   PubMed Web of Science ®Google Scholar
• Holm E, Carlsson KS, Lovdahl S, Lail AE, Abshire TC, Berntorp E. Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network. Haemophilia. 2018;24(4):628–633. doi:10.1111/hae.13473
   PubMed Web of Science ®Google Scholar
• Oladapo A, Wu Y, Lu M, Farahbakhshian S, Ewenstein B. Estimation of the economic burden associated with major surgery due to von Willebrand disease based on claims data from the USA. Blood. 2019;134(1):4692.
   Google Scholar
• Boban A, Lambert CM, Hermans C. VWF-FVIII concentrates in the treatment of inherited von Willebrand disease: a single-centre retrospective study. Haemophilia. 2019;25(4):e300–e303. doi:10.1111/hae.13779
   PubMed Web of Science ®Google Scholar
• De Wee EM, Knol HM, Mauser-Bunschoten EP, et al. Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease. Thromb Haemost. 2011;106(5):885–892. doi:10.1160/TH11-03-0180
   PubMed Web of Science ®Google Scholar
• Batty P, Chen YH, Bowles L, Hart DP, Platton S, Pasi KJ. Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate(R)): a single centre experience. Haemophilia. 2014;20(6):846–853. doi:10.1111/hae.12496
   PubMed Web of Science ®Google Scholar
• Howman R, Barnes C, Curtin J, et al. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE(R), in children with von Willebrand disorder: a multi-centre retrospective review. Haemophilia. 2011;17(3):463–469. doi:10.1111/j.1365-2516.2010.02445.x
   PubMed Web of Science ®Google Scholar
• Khair K, Batty P, Riat R, et al. Wilate use in 47 children with von Willebrand disease: the North London paediatric haemophilia network experience. Haemophilia. 2015;21(1):e44–e50. doi:10.1111/hae.12497
   PubMed Web of Science ®Google Scholar
• Livesey K, Yealy DM, Li J, Moore CG, Ragni MV. Von Willebrand disease in the emergency department. Haemophilia. 2016;22(2):263–267. doi:10.1111/hae.12841
   PubMed Web of Science ®Google Scholar
• Miesbach W, Krekeler S, Wolf Z, Seifried E. Clinical use of Haemate(R) P in von Willebrand disease: a 25-year retrospective observational study. Thromb Res. 2015;135(3):479–484. doi:10.1016/j.thromres.2014.12.017
   PubMed Web of Science ®Google Scholar
• Goudemand J, Bridey F, Claeyssens S, et al. Management of von Willebrand disease with a factor VIII-poor von Willebrand factor concentrate: results from a prospective observational post-marketing study. J Thromb Haemost. 2020;18(8):1922–1933. doi:10.1111/jth.14928
   PubMed Web of Science ®Google Scholar
• Govorov I, Lofgren S, Chaireti R, Holmstrom M, Bremme K, Mints M. Postpartum hemorrhage in women with von Willebrand disease - a retrospective observational study. PLoS One. 2016;11(10):e0164683. doi:10.1371/journal.pone.0164683
   PubMed Web of Science ®Google Scholar
• James AH, Konkle BA, Kouides P, et al. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. Haemophilia. 2015;21(1):81–87. doi:10.1111/hae.12568
   PubMed Web of Science ®Google Scholar
• Abshire TC, Federici AB, Alvarez MT, et al. Prophylaxis in severe forms of von Willebrand’s disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia. 2013;19(1):76–81. doi:10.1111/j.1365-2516.2012.02916.x
   PubMed Web of Science ®Google Scholar
• Castaman G, Coppola A, Zanon E, et al. Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease. Haemophilia. 2013;19(1):82–88. doi:10.1111/hae.12005
   PubMed Web of Science ®Google Scholar
• Federici AB, Gianniello F, Mannucci PM. Secondary long-term prophylaxis in von Willebrand disease: an Italian cohort study. Hematology Meeting Reports. 2005;1:6. doi:10.4081/hmr.v1i6.270
   Google Scholar
• Federici AB, Barillari G, Zanon E, et al. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand’s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. Haemophilia. 2010;16(1):101–110. doi:10.1111/j.1365-2516.2009.02088.x
   PubMed Web of Science ®Google Scholar
• Holm E, Abshire TC, Bowen J, et al. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network. Blood Coagul Fibrinolysis. 2015;26(4):383–388. doi:10.1097/MBC.0000000000000257
   PubMed Web of Science ®Google Scholar
• Halimeh S, Krumpel A, Rott H, et al. Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease. Results of a cohort study. Thromb Haemost. 2011;105(4):597–604. doi:10.1160/TH10-09-0616
   PubMed Web of Science ®Google Scholar
• Berntorp E. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3. Semin Thromb Hemost. 2006;32(6):621–625. doi:10.1055/s-2006-949667
   PubMed Web of Science ®Google Scholar
• Berntorp E, Abshire T. The von Willebrand disease prophylaxis network: exploring a treatment concept. J Thromb Haemost. 2006;4(11):2511–2512. doi:10.1111/j.1538-7836.2006.02179.x
   PubMed Web of Science ®Google Scholar
• James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280–300. doi:10.1182/bloodadvances.2020003265
   PubMed Web of Science ®Google Scholar
• Schinco P, Cultrera D, Valeri F, et al. Cost-consequence analysis of long-term prophylaxis in the treatment of von Willebrand disease in the Italian context. Clinicoecon Outcomes Res. 2015;7:17–25. doi:10.2147/CEOR.S71892
   PubMedGoogle Scholar
• Population Estimate as of January 1, 2021. Institut national de statistique et des études économiques (INSEE); 2021. Available from: https://www.insee.fr/fr/statistiques/1893198. Accessed November 23, 2021.
   Google Scholar
• Weiss HJ, Ball AP, Mannucci PM. Incidence of severe von Willebrand’s disease. N Engl J Med. 1982;307(2):127. doi:10.1056/NEJM198207083070222
   PubMed Web of Science ®Google Scholar
• The World Bank. Population, total - Japan. Available from: https://data.worldbank.org/indicator/SP.POP.TOTL?locations=JP. Accessed November 23, 2021.
   Google Scholar
• The World Bank. Population, Total - Korea, Republic. Available from: https://data.worldbank.org/indicator/SP.POP.TOTL?locations=KR. Accessed April 27, 2022.
   Google Scholar
• Lu M, Oladapo A, Wu Y, Farahbakhshian S, Ewenstein B. Prevalence and burden of major bleeding events in patients with von Willebrand disease based on claims data from the USA. Blood. 2018;132(Suppl 1):2222.
   Google Scholar
• Turan O. Gynaecological problem and their management in women with moderate and severe von Willebrand disease (VWD). Haemophilia. 2020;26(Suppl 4):139–140.
   Google Scholar
• Borel-Derlon A, Goudemand J, Boyer-Neumann C, et al. Gynecological & obstetrical events from a French post-marketing survey of a von Willebrand factor concentrate with a low factor VIII content. J Thromb Haemost. 2011;9(Suppl 2):667–668.
   Google Scholar
• Boyer-Neumann C, Borel-Derlon A, Goudemand J, et al. Management of childbirth in Von Willebrand Disease (VWD) women: results from studies with a von Willebrand factor product with a low content of Factor VIII. Hamostaseologie. 2013;33(1):A42.
   Google Scholar
• Desprez D, Drillaud N, Flaujac C, et al. Efficacy and safety of a recombinant Von Willebrand Factor treatment in patients with inherited Von Willebrand Disease requiring surgical procedures. Haemophilia. 2021;27(2):270–276. doi:10.1111/hae.14242
   PubMed Web of Science ®Google Scholar
• Auerswald G, Bade A, Haubold K, Overberg D, Masurat S, Moorthi C. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study. Haemophilia. 2013;19(3):438–444. doi:10.1111/hae.12075
   PubMed Web of Science ®Google Scholar
• Seaman CD, Ragni MV. Periprocedural management of von Willebrand disease: an institutional experience. Haemophilia. 2019;25(3):e199–e203. doi:10.1111/hae.13718
   PubMed Web of Science ®Google Scholar
• O’Connell M, Singleton E, Byrne MB, Ryan K, White B, O’Donnell J. Efficacy and safety of Wilate following an en masse switch for patients with inherited von Willebrand disease. J Thromb Haemost. 2013;11(2):550.
   Google Scholar
• Proulle V, Trossaert M, Rugeri L, et al. Efficacy and safety of hFVIII/VWF concentrate in a large cohort of patients with von Willebrand disease (VWD) requiring surgical procedures: the French experience. Res Pract Thromb Haemost. 2019;3:389–390.
   Google Scholar